Investor Presentation Q1-Q3 2020

8 Investor presentation First nine months of 2020 OzempicⓇ and RybelsusⓇ continue to expand GLP-1 NBRX and TRX market leadership in the US US GLP-1 NBRx market share NBRX share OzempicⓇ 70% NN GLP-1 RybelsusⓇ -VictozaⓇ -dulaglutide 60% 50% 40% 30% 20% 10% 0% Jun 2019 Source: NBRX-IQVIA National LRX Weekly, Sep 2020 NBRX: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk Novo Nordisk® US GLP-1 TRX market size and market share TRX share OzempicⓇ 70% -NN GLP-1 RybelsusⓇ -VictozaⓇ dulaglutide 60.2% 60% Class growth around 30% 49.6% 50% 44.3% 40% 34.7% 34.5% 30% 20% 26.9% 22.7% 13.5% 12.0% 10% 3.7% 0% Oct Jun Oct 2020 2019 2020

View entire presentation